ARRAKIS THERAPEUTICS
Live / Applied — Opposition pending (as of 06 Jul 2026)
What this means for you
Not registered yet, but its 04 Mar 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers. An opposition to it is pending before the Trademark Trial and Appeal Board, so it will register only if the opposition fails or is withdrawn.
Record
- Serial number
- 99065751
- Mark type
- Word mark
- Filed
- 04 Mar 2025
- Published for opposition
- 10 Mar 2026
- Attorney of record
- JENNIFER INSLEY-PRUITT
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations, namely, small-molecule drugs for the treatment of cancer, neuromuscular, neurodegenerative, hematological, immune and cardiovascular diseases
Owner
- Arrakis Therapeutics, Inc., Waltham, MA, US
- Arrakis Therapeutics, Inc., Waltham, MA, US
Board proceedings on this mark
- Opposition No. 91308612 — Insmed Incorporated v. Arrakis Therapeutics, Inc., filed 06 Jul 2026 (Pending)
- Extension of Time to Oppose No. 99065751 — Insmed Incorporated v. Arrakis Therapeutics, Inc., filed 03 Apr 2026 (Terminated)
Prosecution history
- 08 Jul 2026 — EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
- 06 Jul 2026 — OPPOSITION INSTITUTED NO. 999999
- 03 Apr 2026 — EXTENSION OF TIME TO OPPOSE RECEIVED
- 10 Mar 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 10 Mar 2026 — PUBLISHED FOR OPPOSITION
- 04 Mar 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 11 Feb 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 11 Feb 2026 — EXAMINER'S AMENDMENT ENTERED
- 11 Feb 2026 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 11 Feb 2026 — EXAMINERS AMENDMENT E-MAILED
- 11 Feb 2026 — EXAMINERS AMENDMENT -WRITTEN
- 11 Feb 2026 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 11 Feb 2026 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
- 14 Nov 2025 — NOTIFICATION OF FINAL REFUSAL EMAILED
- 14 Nov 2025 — FINAL REFUSAL E-MAILED